BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Treatment with infigratinib at the Cohort 5 dose level resulted in a significant and robust increase in annual height velocity (AHV), with a mean change of +3.38 cm/year from baseline

BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

JPMorgan cautioned investors ahead of a key clinical readout for BridgeBio this coming July. As a result, the biotech's stock is falling today.

Why BridgeBio Pharma Stock Is Plunging Today

PALO ALTO, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that the updated six month results from Cohort 5 in PROPEL2, a Phase 2 trial of the investigational therapy, infigratinib in children with achondroplasia will be featured in an oral presentation at the Endocrine Society (ENDO) 2023 Annual Conference, taking place in Chicago, Illinois on June 15 – 18, 2023.

BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

- Following treatment, the N-acetylaspartate (NAA) levels of CANaspire participants are consistent with levels seen in individuals with milder Canavan disease based on findings from the Company's natural history study and reports in the scientific literature

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

PALO ALTO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that updated data from CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease, will be presented at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, CA on May 16 – 20, 2023.

BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial developments and executed a needed capital raise in March.

BridgeBio Pharma: A Lot Of Paths To Potential Success

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $1.19 per share a year ago.

BridgeBio Pharma (BBIO) Reports Q1 Loss, Lags Revenue Estimates

- Phase 3 ATTRibute-CM registrational trial of acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) has now completed last patient last visit and remains on track for topline month 30 registrational data to be announced in late July 2023

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

PALO ALTO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas, NV on Wednesday, May 10 at 10:00 am PT.

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference

C3.ai

Comerica

Enovix Corporation

First Republic

LifeStance Health Group

Provention Bio Inc

UMB Financial

Western Alliance Bancorporation

Zions Bancorp

March was a good month for the stock market, with the S&P 500 gaining about 3.5%.

The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023

Apellis Pharma

Growth stocks have been under heavy pressure over the past year. A handful of biotech companies have defied this broader downturn, however.

2 Best Growth Stocks to Buy in April

BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last?

– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by preclinical findings demonstrating its safety profile, continuous, once-daily dosing regimen and synergistic efficacy to treat cancers driven by KRAS mutations

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb's OPDIVO® (nivolumab)

Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism.

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

- BridgeBio has developed a validated bioassay that directly measures glycosylated ⍺ DG, which is central to LGMD2I disease, and enables monitoring of responses to disease-modifying therapies in LGMD2I patients

BridgeBio Pharma Shares Preliminary Findings on Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

- BridgeBio will also share 15-month Phase 2 data and review the Phase 3 clinical trial design of BBP-418, a potential therapeutic for patients with LGMD2I, with initiation of its Phase 3 study expected in mid-2023

BridgeBio Pharma to Present Preliminary Findings on its Novel Bioassay Measuring Glycosylated Alpha-dystroglycan (⍺DG) in Patients with Limb-girdle Muscular Dystrophy Type 2I (LGMD2I)

The Palo Alto-based company's susceptibility to extreme price swings was on display again last week, albeit on a smaller scale. Positive results in a study of BridgeBio's infigratinib candidate sent the stock on a 71% two-day run.

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope

Here is how BridgeBio Pharma (BBIO) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.

Is BridgeBio Pharma (BBIO) Stock Outpacing Its Medical Peers This Year?

Markets sent BridgeBio sharply higher after the company posted clinical Phase 2 results for infigratinib. After the close, BBIO announced a stock sale that would raise $150 million.

What To Do After BridgeBio Pharma Soared By Over 50%

Aclaris Therapeutics

Markets were mixed, with large caps rising as small caps gave up ground. BridgeBio Pharma showed positive trial results for a treatment for a disease that limits growth.

These 2 Biotech Stocks Made Big Monday Moves

Esperion Therapeutics

At least two biotech stocks are seeing increased scrutiny in the options pits, with BridgeBio Pharma  Inc (NASDAQ:BBIO) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions following their respective drug updates.

2 Biotech Stocks Options Traders Are Watching

BridgeBio Pharma Inc shares have soared more than 55% after the company announced positive data from a Phase 2 clinical trial for its investigational therapy infigratinib in children with achondroplasia, a form of short-limbed dwarfism. Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source, BridgeBio noted in a statement.

BridgeBio Pharma shares soar 55% on positive achondroplasia trial results

BridgeBio announced positive phase 2 results for infigratinib in treating children with achondroplasia. The company now plans to move forward with a pivotal phase 3 study of the experimental drug.

Why BridgeBio Pharma Stock Is Skyrocketing Today

There's potentially good news for the medical community and definitely positive news for investors of BridgeBio Pharma (NASDAQ: BBIO ) stock. Reportedly, BridgeBio Pharma published clinical results from a proposed treatment for a rare condition affecting children.

Why Is BridgeBio Pharma (BBIO) Stock Up 60% Today?

BridgeBio Pharma smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume. The post BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study appeared first on Investor's Business Daily.

News for BridgeBio Pharma Inc Stock (BBIO)